VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 28, 2008) - Allon Therapeutics Inc. (TSX:NPC) announced today that in a Phase IIa clinical trial evaluating the potential of its drug AL-208 to prevent or reduce mild cognitive impairment (MCI) in patients who undergo coronary artery bypass graft (CABG) surgery the single-dose had no observable effect in these patients. Neither the placebo nor the treated groups appeared significantly impaired in their cognitive functions post surgery in contrast to the deficits reported in the published literature.
